<DOC>
	<DOCNO>NCT02935023</DOCNO>
	<brief_summary>The goal clinical study determine impact carbon ion radiotherapy ( CIRT ) treatment combination systemic therapy oligo-metastatic prostate cancer . The primary objective : determine disease biochemical progression-free survival man oligo-metastatic ( M1a/b ) prostate cancer undergo systemic therapy definitive radiotherapy primary tumor . The secondary objective : determine local control , overall survival quality life men oligo-metastatic prostate cancer undergo carbon ion radiotherapy</brief_summary>
	<brief_title>Carbon Ion Radiotherapy Treating Patients Undergoing Systemic Therapy Oligo-metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Pathologically confirm adenocarcinoma prostate 2 . Age ≥ 20 &lt; 80 year age 3 . ECOG PS 0 1 4 . Lifeexpectancy ≥1 year 5 . Stage T14 , N01 , M1a/b disease imaging , combine maximum 3 synchronous lesion . 6 . Ability understand willingness sign inform consent 1 . No pathologically confirm adenocarcinoma prostate 2. visceral metastasis 3 . Previous pelvic radiotherapy prostatectomy 4 . Severe systemic disorder</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>